Frontiers in Molecular Biosciences (Feb 2021)

The Multi-Level Mechanism of Action of a Pan-Ras Inhibitor Explains its Antiproliferative Activity on Cetuximab-Resistant Cancer Cells

  • Renata Tisi,
  • Michela Spinelli,
  • Michela Spinelli,
  • Alessandro Palmioli,
  • Cristina Airoldi,
  • Cristina Airoldi,
  • Paolo Cazzaniga,
  • Paolo Cazzaniga,
  • Daniela Besozzi,
  • Daniela Besozzi,
  • Marco S. Nobile,
  • Marco S. Nobile,
  • Elisa Mazzoleni,
  • Simone Arnhold,
  • Luca De Gioia,
  • Luca De Gioia,
  • Rita Grandori,
  • Francesco Peri,
  • Marco Vanoni,
  • Marco Vanoni,
  • Elena Sacco,
  • Elena Sacco

DOI
https://doi.org/10.3389/fmolb.2021.625979
Journal volume & issue
Vol. 8

Abstract

Read online

Ras oncoproteins play a crucial role in the onset, maintenance, and progression of the most common and deadly human cancers. Despite extensive research efforts, only a few mutant-specific Ras inhibitors have been reported. We show that cmp4–previously identified as a water-soluble Ras inhibitor– targets multiple steps in the activation and downstream signaling of different Ras mutants and isoforms. Binding of this pan-Ras inhibitor to an extended Switch II pocket on HRas and KRas proteins induces a conformational change that down-regulates intrinsic and GEF-mediated nucleotide dissociation and exchange and effector binding. A mathematical model of the Ras activation cycle predicts that the inhibitor severely reduces the proliferation of different Ras-driven cancer cells, effectively cooperating with Cetuximab to reduce proliferation even of Cetuximab-resistant cancer cell lines. Experimental data confirm the model prediction, indicating that the pan-Ras inhibitor is an appropriate candidate for medicinal chemistry efforts tailored at improving its currently unsatisfactory affinity.

Keywords